SGX Pharmaceuticals - Best Pharma Stocks of 2007
Company: SGX Pharmaceuticals
Starting stock price: $3.314
Ending stock price: $4.76
Percent Change: 43.81%
Details: SGX is focused on developing cancer drugs, and uses its FAST technology to identify and optimize small molecule fragments that bind to specific targets. In 2007 SGX filed an IND for SGX523 for solid tumors. The company also has a number of preclinical programs for relapsed/refractory chronic myelogenous leukemia (CML) and front-line CML.
More News:
SGX Initiates Phase I Trials for SGX523. Report
SGX shares tank on late-stage trial failure. Report
More stories about SGX Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment